Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: An in vivo 11C-harmine positron emission tomography study

Journal of Cerebral Blood Flow and Metabolism

Volumn 32, Issue 3, 2012, Pages 443-446

  Sacher, Julia ^a,b,c   Rabiner, Eugenii A ^d   Clark, Michael ^a,b   Rusjan, Pablo ^a   Soliman, Alexandra ^a,b   Boskovic, Rada ^a,d,e   Kish, Stephen J ^a   Wilson, Alan A ^a   Houle, Sylvain ^a   Meyer, Jeffrey H ^a,b  

^a Vivian M Rakoff PET Imaging Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d GLAXOSMITHKLINE   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

5 HT; brain imaging; depression; dopamine; Parkinson's disease; positron emission tomography

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CARBIDOPA; HARMINE C 11; LEVODOPA; MONOAMINE; RADIOPHARMACEUTICAL AGENT; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING KINETICS; BLOOD SAMPLING; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MOLECULAR DYNAMICS; MOOD DISORDER; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN METABOLISM; RADIOACTIVITY;

CARBIDOPA; CARBON RADIOISOTOPES; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DRUG COMBINATIONS; HARMINE; HUMANS; LEVODOPA; MONOAMINE OXIDASE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN BINDING; SEROTONIN; SUBSTRATE SPECIFICITY; TIME FACTORS; TRYPTOPHAN;

EID: 84857788849     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2011.184     Document Type: Article

References (15)

1. Alia-Klein N, Goldstein RZ, Kriplani A, Logan J, Tomasi D, Williams B, Telang F, Shumay E, Biegon A, Craig IW, Henn F, Wang GJ, Volkow ND, Fowler JS (2008) Brain monoamine oxidase A activity predicts trait aggression. J Neurosci 28:5099-104
2. de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ (2001) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 49:298-303
3. Ferrer A, Artigas F (1994) Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain. Eur J Pharmacol 263:227-34
4. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP (1996) Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93:14065-9
5. Ginovart N, Meyer JH, Boovariwala A, Hussey D, Rabiner EA, Houle S, Wilson AA (2006) Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 26:330-44
6. Lieben CK, Blokland A, Westerink B, Deutz NE (2004) Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein-carbohydrate mixture in the adult rat. Neurochem Int 44:9-16
7. Manoli I, Le H, Alesci S, McFann KK, Su YA, Kino T, Chrousos GP, Blackman MR (2005) Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells. FASEB J 19:1359-61
8. Mendlewicz J, Youdim MB (1980) Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord 2:137-46
9. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N,Wilson AA, Houle S (2006) Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch General Psychiatry 63:1209-16
10. Meyer JH, Wilson AA, Sagrati S, Miler L, Rusjan PM, Bloomfield PM, Clark M, Sacher J, Voineskos AN, Houle S (2009) Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery and recurrence. Arch General Psychiatry 66(12):1304-12
11. Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, Bain EE, Luckenbaugh DA, Herscovitch P, Charney DS, Drevets WC (2004) Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch General Psychiatry 61:765-73
12. Pizzinat N, Marchal-Victorion S, Maurel A, Ordener C, Bompart G, Parini A (2003) Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors. Am J Physiol 284:F167-74
13. Sacher J, Wilson AA, Houle S, Rusjan P, Hassan S, Bloomfield PM, Stewart DE, Meyer JH (2010) Elevated brain monoamine oxidase A binding in the early postpartum period. Arch General Psychiatry 67:468-74
14. Saura J, Kettler R, Da Prada M, Richards JG (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12:1977-99
15. Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev 7:295-309